1025 related articles for article (PubMed ID: 17911986)
1. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
2. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
3. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous and mucosal manifestations of inflammatory bowel diseases].
Károlyi Z; Erós N; Ujszászy L; Nagy G
Orv Hetil; 2000 Jun; 141(25):1391-5. PubMed ID: 10934882
[TBL] [Abstract][Full Text] [Related]
10. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review.
Apgar JT
Semin Dermatol; 1991 Sep; 10(3):138-47. PubMed ID: 1931561
[TBL] [Abstract][Full Text] [Related]
11. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease.
Menachem Y; Gotsman I
Isr Med Assoc J; 2004 Feb; 6(2):88-90. PubMed ID: 14986464
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic inflammatory bowel diseases].
Lémann M
Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
[TBL] [Abstract][Full Text] [Related]
13. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous manifestations in inflammatory bowel disease.
Tromm A; May D; Almus E; Voigt E; Greving I; Schwegler U; Griga T
Z Gastroenterol; 2001 Feb; 39(2):137-44. PubMed ID: 11253504
[TBL] [Abstract][Full Text] [Related]
15. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases.
De Simone C; Sollena P; Coco V; Caldarola G
G Ital Dermatol Venereol; 2013 Apr; 148(2):175-84. PubMed ID: 23588143
[TBL] [Abstract][Full Text] [Related]
16. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients.
Esmailzadeh A; Yousefi P; Farhi D; Bachmeyer C; Cosnes J; Berenbaum F; Duriez P; Aractingi S; Khosrotehrani K
Dermatology; 2009; 219(3):263-7. PubMed ID: 19684381
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
[TBL] [Abstract][Full Text] [Related]
20. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
Rahier JF; Buche S; Peyrin-Biroulet L; Bouhnik Y; Duclos B; Louis E; Papay P; Allez M; Cosnes J; Cortot A; Laharie D; Reimund JM; Lémann M; Delaporte E; Colombel JF;
Clin Gastroenterol Hepatol; 2010 Dec; 8(12):1048-55. PubMed ID: 20728573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
